Exclusive: OpenAI has acquired Orchestra Bio
OpenAI has acquired biotech startup Orchestra Bio to accelerate drug development timelines and integrate artificial intelligence agents into pharmaceutical research workflows. The acquisition brings Orchestra Bio's team and technology into Rosalind, OpenAI's life sciences research platform. Founded in 2022, Orchestra Bio builds tools and intelligent management platforms that coordinate drug discovery processes and help pharmaceutical teams manage research delays. The exact financial terms of the deal were not disclosed, though the startup had previously raised about $20 million from venture capital firms including Andreessen Horowitz by 2025.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ OpenAI has acquired Orchestra Bio, a startup that develops AI agents to manage drug development workflows and pharmaceutical research programs.
- ✓ Orchestra Bio's technology and team will be integrated into Rosalind, OpenAI's suite of life sciences models and tools.
- ✓ Orchestra Bio was founded in 2022 and had raised approximately $20 million from venture capital firms such as Andreessen Horowitz by 2025.
- ✓ The acquisition of Orchestra Bio impacted Veeva Systems stock.
What changed
OpenAI completed its acquisition of drug-development platform Orchestra Bio to bolster its life sciences division and integrate the startup's team into the Rosalind platform.
Live updates
-
OpenAI Acquires Drug-Development Startup Orchestra Bio
OpenAI has acquired biotech startup Orchestra Bio to accelerate drug development timelines and integrate artificial intelligence agents into pharmaceutical research workflows. The acquisition brings Orchestra Bio's team and technology into Rosalind, OpenAI's life sciences research platform. Founded in 2022, Orchestra Bio builds tools and intelligent management platforms that coordinate drug discovery processes and help pharmaceutical teams manage research delays. The exact financial terms of the deal were not disclosed, though the startup had previously raised about $20 million from venture capital firms including Andreessen Horowitz by 2025.
Why it matters
The transaction intensifies a growing scientific rivalry in the artificial intelligence sector, particularly against competitor Anthropic, which recently purchased Coefficient Bio for $400 million. Tech companies are heavily targeting the pharmaceutical and biological sciences space to develop specialized AI models and laboratory tools. Integration of Orchestra Bio into Rosalind aims to place autonomous AI agents directly inside drug development programs to compress long research timelines.
What is confirmed
- OpenAI has acquired Orchestra Bio, a startup that develops AI agents to manage drug development workflows and pharmaceutical research programs.
- Orchestra Bio's technology and team will be integrated into Rosalind, OpenAI's suite of life sciences models and tools.
- Orchestra Bio was founded in 2022 and had raised approximately $20 million from venture capital firms such as Andreessen Horowitz by 2025.
- The acquisition of Orchestra Bio impacted Veeva Systems stock.
- The financial terms of the acquisition were not disclosed.
What to watch next
- Further integration details regarding Orchestra Bio technology within Rosalind
- Competitor responses from Anthropic or other science-focused AI firms
- Broader impacts on pharmaceutical software providers such as Veeva Systems
confidence 100%Sources used for this update (14)
- help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
- Axios — Exclusive: OpenAI has acquired Orchestra Bio
- TechCrunch — OpenAI acquires startup Orchestra Bio to beef up its biotech business
- The Information — OpenAI Buys Drug Development Company Orchestra Bio
- GuruFocus — OpenAI Acquisition of Orchestra Bio Shakes Veeva Systems (VEEV) Stock
- PharmTech.com — OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
- www.webpronews.com — OpenAI Buys Orchestra Bio to Put AI Agents Inside Drug Development Programs - WebProNews
- en.wowtale.net — OpenAI Buys Drug-Development AI Startup as Science Rivalry With Anthropic Heats Up - WOWTALE
- gptonline.ai — OpenAI Acquires Orchestra Bio To Boost Rosalind Biotech AI - 챗GPT,등록 없이 AI 챗봇을 사용해 보세요
- siliconangle.com — In AI, it's a tale of two diverging investor classes - SiliconANGLE
- gigazine.net — OpenAI acquires pharmaceutical development platform Orchestra Bio. - GIGAZINE
- digg.com — OpenAI acquires Orchestra Bio to build on its life sciences tools · Digg
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community